April 25, 2022Letter Agreement • May 9th, 2022 • Neogenomics Inc • Services-testing laboratories • Delaware
This letter agreement (this “Agreement”) confirms the terms and conditions of your role as Executive Chair and Principal Executive Officer of NeoGenomics, Inc. (the “Company”), effective as of April 19, 2022 (except as otherwise provided herein). At such time as a new Chief Executive Officer of the Company commences employment with the Company, or such other date as may be agreed to by you and the Board (any such date, the “Transition Date”), this Agreement shall terminate and no longer be effective.
